Furosemide-induced genotoxicity and cytotoxicity in the hepatocytes, but weak genotoxicity in the bone marrow cells of mice

Fundamental and Clinical Pharmacology

Volumn 26, Issue 3, 2012, Pages 383-392

  Mondal, Sambhu Charan ^a   Tripathi, Durga Nand ^a   Vikram, Ajit ^a   Ramarao, Poduri ^a   Jena, Gopabandhu B ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bone marrow; Cytotoxicity; Furosemide; Genotoxicity; Liver; Mice; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FUROSEMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CHROMOSOME ABERRATION; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG DOSE COMPARISON; GENOTOXICITY; IN VIVO STUDY; LIVER CELL; LIVER TOXICITY; MALE; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STRUCTURAL CHROMOSOME ABERRATION;

ANIMALS; BONE MARROW CELLS; CYTOTOXINS; DNA DAMAGE; FUROSEMIDE; HEPATOCYTES; MALE; MICE; RANDOM ALLOCATION;

EID: 84860243890     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.00927.x     Document Type: Article

References (40)

1. Anguita M., Toledano F., León C., Castillo J.C. Hypertension, hypertensive heart disease and heart failure. Role of loop diuretics. Med. Clín. (2008) 131 660-664.
2. Speers A.G., Lwaleed B.A., Featherstone J.M., Sallis B.J., Cooper A.J. Furosemide reverses multidrug resistance status in bladder cancer cells in vitro. J. Clin. Pathol. (2006) 59 912-915.
3. Isidori M., Nardelli A., Parrella A., Pascarella L., Previtera L. A multispecies study to assess the toxic and genotoxic effect of pharmaceuticals: furosemide and its photoproduct. Chemosphere (2006) 63 785-793.
4. Mitchell J.R., Nelson W.L., Potter W.Z., Sasame H.A., Jollow D.J. Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite. J. Pharmacol. Exp. Ther. (1976) 199 41-52.
5. Spitznagle L.A., Wirth P.J., Boobis S.W., Thorgeirsson S.S., Nelson W.L. The role of biliary excretion in the hepatotoxicity of furosemide in the mouse. Toxicol. Appl. Pharmacol. (1977) 39 283-294.
6. Walker R.M., McElligott T.F. Furosemide induced hepatotoxicity. J. Pathol. (1981) 135 301-314.
7. Rybak L.P., Whitworth C., Scott V., Weberg A. Ototoxicity of furosemide during development. Laryngoscope (1991) 101 1167-1174.
8. Schwartz G.H. Ototoxicity of furosemide. N. Engl. J. Med. (1970) 283 434.
9. Bucher J.R., Huff J., Haseman J.K., Eustis S.L., Davis W.E. Jr, Meierhenry E.F. Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. 2. Furosemide. J. Appl. Toxicol. (1990) 10 369-378.
10. Zuccato E., Castiglioni S., Fanelli R. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J. Hazard. Mater. (2005) 122 205-209.
11. Huschek G., Hansen P.D., Maurer H.H., Krengel D., Kayser A. Environmental risk assessment of medicinal products for human use according to European Commission recommendations. Environ. Toxicol. (2004) 19 226-240.
12. Bucher J.R. Toxicology and carcinogenesis studies of furosemide (CAS No. 54-31-9) in F344/N rats and B6C3F1 mice (feed studies). Natl. Toxicol. Program. Tech. Rep. Ser. (1989) 356 1-190.
13. Brambilla G., Martelli A. Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat. Res. Rev. (2006) 612 115-149.
14. Brambilla G., Martelli A. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat. Res. Rev. (2009) 681 209-229.
15. Kirpnick Z., Homiski M., Rubitski E. et al. Yeast DEL assay detects clastogens. Mutat. Res. (2005) 582 116-134.
16. Sasaki M., Sugimura K., Yoshida M.A., Abe S. Cytogenetic effects of 60 chemicals on cultured human and Chinese hamster cells. Kromosomo II (1980) 20 574-584.
17. Marquardt H., Siebert D. Ein neuer host mediated assay (Urinversuch) zum Nachweis mutagener Stoffe mitSaccharomyces cerevisiae. Naturwissenschaften (1971) 58 568-568.
18. Jameela X., Subramanyam S., Sadasivan G. Clastogenic effects of furosemide on human leukocytes in culture. Mutat. Res. (1979) 66 69-74.
19. Williams D.P., Antoine D.J., Butler P.J. et al. The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore. J. Pharmacol. Exp. Ther. (2007) 322 1208-1220.
20. Rogers L.K., Valentine C.J., Szczpyka M., Smith C.V. Effects of hepatotoxic doses of acetaminophen and furosemide on tissue concentrations of CoASH and CoASSG in vivo. Chem. Res. Toxicol. (2000) 13 873-882.
21. Tripathi K.D. Essentials of Medical Pharmacology. Jaypee Brothers Medical Publication, New Delhi, 2003.
22. Todd K.S., Hudes M., Calloway D.H. Food intake measurement: problems and approaches. Am. J. Clin. Nut. (1983) 37 139-146.
23. Tripathi D.N., Jena G.B. Intervention of astaxanthin against cyclophosphamide-induced oxidative stress and DNA damage: a study in mice. Chem. Biol. Interact. (2009) 180 398-406.
24. Tripathi D.N., Pawar A.A., Vikram A., Ramarao P., Jena G.B. Use of the alkaline comet assay for the detection of transplacental genotoxins in newborn mice. Mutat. Res. (2008) 653 134-139.
25. Grant W.F., Owens E.T. Chromosome aberration assays in Pisum for the study of environmental mutagens. Mutat. Res. Rev. Mutat. Res. (2001) 488 93-118.
26. Burlinson B., Tice R.R., Speit G. et al. Fourth International Workgroup on Genotoxicity testing: results of the in vivo Comet assay workgroup. Mut. Res. Genet. Toxicol. Environ. Mutagenesis (2007) 627 31-35.
27. Padmanabhan S., Tripathi D.N., Vikram A., Ramarao P., Jena G.B. Cytotoxic and genotoxic effects of methotrexate in germ cells of male Swiss mice. Mutat. Res. (2008) 655 59-67.
28. Burton K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. (1956) 62 315.
29. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. (1992) 119 493-501.
30. Randle L.E., Goldring C.E.P., Benson C.A. et al. Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice. Toxicology (2008) 243 249-260.
31. Park K.B., Dalton-Brown E., Hirst C., Williams D.P. Selection of new chemical entities with decreased potential for adverse drug reactions. Eur. J. Pharmacol. (2006) 549 1-8.
32. Williams D.P. Toxicophores: investigations in drug safety. Toxicology (2006) 226 1-11.
33. Lebedev A.A., Petrenko N.A. The antioxidative properties of furosemide in renal ischemia. Eksp. Klin. Farmakol. (1996) 59 28-30.
34. Lahet J.J., Lenfant F., Courderot-Masuyer C. et al. In vivo and in vitro antioxidant properties of furosemide. Life Sci. (2003) 73 1075-1082.
35. Klaunig J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. (2004) 44 239-267.
36. Wong S.G., Card J.W., Racz W.J. The role of mitochondrial injury in bromobenzene and furosemide induced hepatotoxicity. Toxicol. Lett. (2000) 116 171-181.
37. Antoine D.J., Williams D.P., Regan S.L., Park B.K. Formation of cytotoxic protein reactive metabolites from furosemide: biological consequences of drug metabolism. Toxicology (2007) 240 157-168.
38. Preston R.J., Dean B.J., Galloway S., Holden H., McFee A.F., Shelby M. Mammalian in vivo cytogenetic assays. Analysis of chromosome aberrations in bone marrow cells. Mutat. Res. (1987) 189 157-165.
39. Konca K., Lankoff A., Banasik A. et al. A cross-platform public domain PC image-analysis program for the comet assay. Mutat. Res. (2003) 534 15-20.
40. Yuengsrigul A., Chin T.W., Nussbaum E. Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. Ann. Allergy Asthma Immunol. (1999) 63 559-566.